242 related articles for article (PubMed ID: 17694082)
1. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells.
Yang XJ; Ullah M
Oncogene; 2007 Aug; 26(37):5408-19. PubMed ID: 17694082
[TBL] [Abstract][Full Text] [Related]
2. MOZ fusion proteins in acute myeloid leukaemia.
Troke PJ; Kindle KB; Collins HM; Heery DM
Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
[TBL] [Abstract][Full Text] [Related]
3. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.
Katsumoto T; Yoshida N; Kitabayashi I
Cancer Sci; 2008 Aug; 99(8):1523-7. PubMed ID: 18754862
[TBL] [Abstract][Full Text] [Related]
4. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes.
Ullah M; Pelletier N; Xiao L; Zhao SP; Wang K; Degerny C; Tahmasebi S; Cayrou C; Doyon Y; Goh SL; Champagne N; Côté J; Yang XJ
Mol Cell Biol; 2008 Nov; 28(22):6828-43. PubMed ID: 18794358
[TBL] [Abstract][Full Text] [Related]
5. MOZ is essential for maintenance of hematopoietic stem cells.
Katsumoto T; Aikawa Y; Iwama A; Ueda S; Ichikawa H; Ochiya T; Kitabayashi I
Genes Dev; 2006 May; 20(10):1321-30. PubMed ID: 16702405
[TBL] [Abstract][Full Text] [Related]
6. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF.
Moore SD; Herrick SR; Ince TA; Kleinman MS; Dal Cin P; Morton CC; Quade BJ
Cancer Res; 2004 Aug; 64(16):5570-7. PubMed ID: 15313893
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
Shima H; Yamagata K; Aikawa Y; Shino M; Koseki H; Shimada H; Kitabayashi I
Int J Hematol; 2014 Jan; 99(1):21-31. PubMed ID: 24258712
[TBL] [Abstract][Full Text] [Related]
8. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.
Champagne N; Pelletier N; Yang XJ
Oncogene; 2001 Jan; 20(3):404-9. PubMed ID: 11313971
[TBL] [Abstract][Full Text] [Related]
9. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2.
Pelletier N; Champagne N; Stifani S; Yang XJ
Oncogene; 2002 Apr; 21(17):2729-40. PubMed ID: 11965546
[TBL] [Abstract][Full Text] [Related]
10. Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin.
Ali M; Yan K; Lalonde ME; Degerny C; Rothbart SB; Strahl BD; Côté J; Yang XJ; Kutateladze TG
J Mol Biol; 2012 Dec; 424(5):328-38. PubMed ID: 23063713
[TBL] [Abstract][Full Text] [Related]
11. Recognition of unmodified histone H3 by the first PHD finger of bromodomain-PHD finger protein 2 provides insights into the regulation of histone acetyltransferases monocytic leukemic zinc-finger protein (MOZ) and MOZ-related factor (MORF).
Qin S; Jin L; Zhang J; Liu L; Ji P; Wu M; Wu J; Shi Y
J Biol Chem; 2011 Oct; 286(42):36944-55. PubMed ID: 21880731
[TBL] [Abstract][Full Text] [Related]
12. MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease.
Yang XJ
Biochim Biophys Acta; 2015 Aug; 1853(8):1818-26. PubMed ID: 25920810
[TBL] [Abstract][Full Text] [Related]
13. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia.
Esteyries S; Perot C; Adelaide J; Imbert M; Lagarde A; Pautas C; Olschwang S; Birnbaum D; Chaffanet M; Mozziconacci MJ
Leukemia; 2008 Mar; 22(3):663-5. PubMed ID: 17805331
[No Abstract] [Full Text] [Related]
14. Reconstitution of active and stoichiometric multisubunit lysine acetyltransferase complexes in insect cells.
Yan K; Wu CJ; Pelletier N; Yang XJ
Methods Mol Biol; 2012; 809():445-64. PubMed ID: 22113293
[TBL] [Abstract][Full Text] [Related]
15. An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets.
Falk H; Connor T; Yang H; Loft KJ; Alcindor JL; Nikolakopoulos G; Surjadi RN; Bentley JD; Hattarki MK; Dolezal O; Murphy JM; Monahan BJ; Peat TS; Thomas T; Baell JB; Parisot JP; Street IP
J Biomol Screen; 2011 Dec; 16(10):1196-205. PubMed ID: 22086725
[TBL] [Abstract][Full Text] [Related]
16. MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
Yin H; Glass J; Blanchard KL
Mol Cancer; 2007 Aug; 6():51. PubMed ID: 17697320
[TBL] [Abstract][Full Text] [Related]
17. Chronic versus acute myelogenous leukemia: a question of self-renewal.
Jamieson CH; Weissman IL; Passegué E
Cancer Cell; 2004 Dec; 6(6):531-3. PubMed ID: 15607956
[TBL] [Abstract][Full Text] [Related]
18. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
Huntly BJ; Shigematsu H; Deguchi K; Lee BH; Mizuno S; Duclos N; Rowan R; Amaral S; Curley D; Williams IR; Akashi K; Gilliland DG
Cancer Cell; 2004 Dec; 6(6):587-96. PubMed ID: 15607963
[TBL] [Abstract][Full Text] [Related]
19. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L
Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes.
Klein BJ; Lalonde ME; Côté J; Yang XJ; Kutateladze TG
Epigenetics; 2014 Feb; 9(2):186-93. PubMed ID: 24169304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
